Why the score exists
CHA₂DS₂-VASc was developed to address a weakness in its predecessor CHADS₂: far too many patients ended up in an intermediate category in which the decision on anticoagulation became a guess. By adding vascular disease, female sex and a finer age stratification, CHA₂DS₂-VASc moves most of these patients into a clearly low or a clearly increased risk category.
The score is therefore not primarily a tool for finding high-risk patients — it is a tool for reliably identifying those whose risk is so low that anticoagulation is not warranted.
Interpretation in daily practice
The threshold differs between the sexes, because female sex in itself gives one point without in isolation implying increased risk. A woman with only the sex point carries the same risk as a man with zero points.
- Man 0 points · woman 1 point — anticoagulation can be withheld.
- Man 1 point — consider after shared decision-making.
- Man ≥ 2 · woman ≥ 3 — oral anticoagulation is recommended.
A DOAC is preferred over warfarin unless there is a mechanical valve prosthesis or moderate to severe mitral stenosis.
Pitfalls
The score applies to non-valvular atrial fibrillation. With a mechanical valve prosthesis or significant mitral stenosis, anticoagulation is indicated whatever the score, and CHA₂DS₂-VASc must not be used to justify withholding it.
The risk is not static. A patient who today scores zero crosses the threshold simply by growing older, and should therefore be reassessed annually.
Bleeding risk is weighed separately — HAS-BLED is intended to identify modifiable risk factors, not to determine whether anticoagulation should be given.
